University of Virginia Cancer Center researchers have explained the failure of immune checkpoint therapy for ovarian cancer ...

To provide updated guidance regarding neoadjuvant chemotherapy (NACT) and primary cytoreductive surgery (PCS) among patients with stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal ...

The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

Neoadjuvant chemotherapy for advanced ovarian cancer was initially administered as an alternative treatment for patients not suitable for primary debulking surgery (PDS) because of unresectable ...

W omen diagnosed with ovarian cancer may initially respond well to chemotherapy, but the majority of them will develop resistance to treatment and die from the disease. Now Northwestern Medicine ...

Traditionally, chemotherapy was given after surgery (primary cytoreductive surgery (PCRS) and adjuvant chemotherapy). However, chemotherapy can be used before surgery (neoadjuvant chemotherapy (NACT) ...

Patients with advanced ovarian cancer are known to have a 20–30% chance of survival, even when undergoing extensive chemotherapy. Xia Wu and co-workers now present evidence that the immune ...

Armstrong and colleagues investigated the efficacy of farletuzumab as a single agent or in combination with standard chemotherapy in patients with relapsed ovarian cancer following first-line therapy.

with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell/neuroendocrine prostate ... Jan. 15, 2025 — Patients with a common aggressive ...